TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00678145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Study: NCT03388463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 80 mg continues infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Omeprazole 40 mg single daily dose.
Study: NCT00114790

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: boronophenylalanine-based BNCT
Description: Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
Study: NCT01022398

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol/placebo
Description: 10,000 IU by mouth weekly for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol/placebo
Description: 10,000 IU by mouth weekly for 6 months
Study: NCT00624455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02452372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: givosiran (ALN-AS1)
Description: Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: calculated volume to match active comparator
Study: NCT00292500

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Automated distal anastomotic device
Description: CABG
Study: NCT01977235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study: NCT02658422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Montelukast
Description: Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Montelukast
Description: Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Montelukast
Description: Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
Study: NCT03750851

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson \& Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPPACPF
Description: In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser
Description: In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LaserCPPACPF
Description: In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
Study: NCT04147468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Strength Training
Description: For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
Study: NCT04009941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: 4.5mg per cycle, 24 hours after chemotherapy
Study: NCT00734669

Intervention type: DRUG
Intervention: Glibenclamide
Description: Taking a single dose of 3.5 mg glibenclamide
Study: NCT02762513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Study: NCT04278885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: 300mg Lanadelumab s.c. administration every 2 weeks
Study: NCT04304131

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Earlytect Colon Cancer
Description: A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Earlytect Colon Cancer
Description: A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Earlytect Colon Cancer
Description: A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer
Study: NCT02574533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
Study: NCT00135603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin/clavulanate potassium
Description: 1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: ablation of the appendix by laparotomy or laparoscopy
Study: NCT01817738

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CV9104
Description: Intradermal injection of CV9104

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of placebo
Study: NCT01961479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT for patients with PMS
Description: Internet-based cognitive-behavioural self-help treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: During the waiting period, participants receive no treatment.
Study: NCT04290702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional analgesia for labor
Description: three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional analgesia for labor
Description: three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional analgesia for labor
Description: three commonly used regional analgesic techniques are used, with local anesthetic ropivacaine, opioid fentanyl, parturient controlled epidural analgesia
Study: NCT03932071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Study: NCT04295070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-RSV
Description: Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-RSV
Description: Codon deoptimized, live-attenuated vaccine against RSV delivered intranasally via dropper

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Saline (0.9%) administered via dropper
Study: NCT02393391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuroelectrics STARSTIM

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuroelectrics STARSTIM
Study: NCT03390413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot
Description: Renal cancer treated with robotic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Renal cancer treated with cryoablation
Study: NCT04693052

Intervention type: OTHER
Intervention: No interventions
Description: This is a self-reported survey study about receiving mental health care during the COVID-19 pandemic
Study: NCT00870337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT00188630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose solution
Study: NCT04307342

Intervention type: PROCEDURE
Intervention: MIPO with Extra-articular Distal Humeral Anatomical Plate
Description: MIPO with Extra-articular Distal Humeral Anatomical Plate
Study: NCT03848299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Single Arm
Description: All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants.
Study: NCT03646448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
Study: NCT05233657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX11502MA
Description: Oral capsule
Study: NCT00969982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone+misoprostol
Description: single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol+placebo
Description: placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
Study: NCT05233657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT02201160

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega 3
Description: Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3
Description: Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
Study: NCT04162210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.
Study: NCT02617901

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Left hand DXA
Description: All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order.
Study: NCT01417013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra
Description: Lubricant Eye Drops

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive
Description: Lubricant eye drops
Study: NCT01131013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.
Study: NCT04162210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pom/dex (Pomalidomide plus low dose Dexamethasone)
Description: Pomalidomide and Dexamethasone will be administered.
Study: NCT02651428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutrolin
Description: Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
Study: NCT02911766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine 0.2% Mouthrinse
Description: Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12% mouthrinse
Description: Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.06% mouthrinse
Description: Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
Study: NCT04737473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opiod Free Anesthesia
Description: The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opiod Free Anesthesia
Description: The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
Study: NCT01291901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NP2
Description: NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
Study: NCT01193400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study: NCT03015805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency Management (CM) utilizes behavior modification \& cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks.
Study: NCT01131013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 375 mg CK-2017357
Description: 375 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 375 mg CK-2017357
Description: 375 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 375 mg CK-2017357
Description: 375 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 375 mg CK-2017357
Description: 375 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 375 mg CK-2017357
Description: 375 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 375 mg CK-2017357
Description: 375 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg CK-2017357
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study: NCT03015805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Probation as Usual
Description: Standard services that a young person would receive while under probation supervision in the state of Oregon.